

**ERGENIX LIMITED**

**UNAUDITED**

**FINANCIAL STATEMENTS**

**INFORMATION FOR FILING WITH THE REGISTRAR**

**FOR THE YEAR ENDED 31 DECEMBER 2022**

**ERGENIX LIMITED**  
**REGISTERED NUMBER: 13145253**

**STATEMENT OF FINANCIAL POSITION**  
**AS AT 31 DECEMBER 2022**

	Note	2022 £	2021 £
<b>Fixed assets</b>			
Investments	4	804,002	804,002
		<u>804,002</u>	<u>804,002</u>
Creditors: amounts falling due within one year	5	(3,652)	(1,852)
<b>Net current liabilities</b>		<u>(3,652)</u>	<u>(1,852)</u>
<b>Total assets less current liabilities</b>		800,350	802,150
Creditors: amounts falling due after more than one year	6	(404,000)	(404,000)
<b>Net assets</b>		<u><u>396,350</u></u>	<u><u>398,150</u></u>
<b>Capital and reserves</b>			
Called up share capital		50	50
Share premium account		399,900	399,900
Profit and loss account		(3,600)	(1,800)
		<u><u>396,350</u></u>	<u><u>398,150</u></u>

**STATEMENT OF FINANCIAL POSITION (CONTINUED)**  
**AS AT 31 DECEMBER 2022**

---

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

**Mr Gagan Kumar Jairath**  
Director

**Mr Zaheer Mohammed**  
Director

Date: 23 August 2023

The notes on pages 3 to 4 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2022**

---

**1. General information**

Ergenix Limited is a private company, limited by share capital, incorporated in England and Wales under registration number 13145253. The address of the registered office of the company is situated at 16 - 20 St Augustines Gate, Hedon, Hull, East Ridings of Yorkshire, HU12 8EX.

**2. Accounting policies**

**2.1 Basis of preparation of financial statements**

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

**2.2 Valuation of investments**

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Income statement for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

**2.3 Debtors**

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

**2.4 Cash and cash equivalents**

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

**2.5 Creditors**

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

**3. Employees**

The average monthly number of employees, including directors, during the year was 2 (2021 - 2).

---

ERGENIX LIMITED

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2022

---

4. Fixed asset investments

	Unlisted investments £
<b>Cost or valuation</b>	
At 1 January 2022	804,002
At 31 December 2022	<u>804,002</u>

The company owns 100% issued share capital of Caring Nationwide Limited and Faith Pharma Limited.

5. Creditors: Amounts falling due within one year

	2022 £	2021 £
Directors loan account	52	52
Accruals and deferred income	3,600	1,800
	<u>3,652</u>	<u>1,852</u>

6. Creditors: Amounts falling due after more than one year

	2022 £	2021 £
Amounts owed to subsidiary company	404,000	404,000
	<u>404,000</u>	<u>404,000</u>

7. Controlling party

There is no controlling party.



This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.